A federal judge has blocked attempts by NuvaRing manufacturer Merck and its subsidiary to prevent the release of documents that may contain detrimental information about the safety of the NuvaRing birth control device. These companies argued that some of the documents contain ‘misinformation’ about NuvaRing that could damage their reputation.
The judge rejected these arguments and issued an order for the documents to be made available to the public, as well as for the NuvaRing trial on May 6, 2013. The lawsuit was filed by a 33-year old woman who was using this dangerous birth control device when she developed pulmonary embolism. She suffered persistent breathing problems and was admitted to hospital. Her problem was diagnosed as pulmonary embolism (PE) of the right lung. She was immediately advised to stop using the contraceptive.
PE is a condition in which a blood clot blocks the main artery of the lung or one of its branches. In acute cases, PE can even prove fatal. Our Chicago NuvaRing lawyers are deeply concerned that neither NuvaRing’s manufacturers nor the FDA adequately warned the public about the risks associated with the use of this birth control device.
In 2011, Marie Claire reported the case of a 26-year-old woman who had a brush with death due to the development of a blood clot caused by her NuvaRing device. This dangerous device is believed to be responsible for hundreds of other serious injuries and even deaths.
NuvaRing is made of an artificial material called ethylene-vinyl-acetate. This ring is supposed to release estrogen and progestin. It is estimated that over 1.5 million women worldwide use NuvaRing. According to IMS Health, a health-care information company, more than 5.5 million prescriptions were written in the U.S. in 2010.
Though the FDA approved NuvaRing in 2001, the agency acknowledged several years earlier that NuvaRing may lead to an increased risk of blood clots, along with all products containing desogestrel. In 2005, the FDA ordered Merck to change the NuvaRing warning label to include more information about its side effects, interactions with other drugs, and patient restrictions. The FDA has since received several appeals to ban the NuvaRing contraceptive device, but has not yet issued a black box warning alerting patients to its adverse effects.
Studies continue to prove the ill effects of synthetic hormonal intrauterine devices such as NuvaRing. A study published in the June 14, 2012 issue of the New England Journal of Medicine reported that women who used devices such as the NuvaRing were three times more likely to suffer heart attacks and strokes compared to women using other forms of hormonal birth control.
Another recent article revealed that as of September 3, 2012, more than
8,418 people reported side effects from the Nuvaring. Deep vein thrombosis
tops the list with 3,434 reports. Other side effects include pulmonary
embolism, anxiety, headache, migraine, depression, nausea, thrombosis,
hypercoagulation, insomnia and metrorrhagia or uterine bleeding. So far,
the FDA has received more than 1,000 reports of blood clot injury or death
in NuvaRing users.
There are many alternative contraceptive devices, both intrauterine and oral, that are safe and effective. Women currently on NuvaRing are advised to consult with their physician and switch to a safer and healthier alternative.
If you or any one you know is suffering the adverse effects of NuvaRing, you need to understand your legal rights. Expert NuvaRing attorneys can help you get the compensation you are entitled to.